Cardiovascular diseases Publications

• The risk of developing cardiovascular disease is increased for prostate cancer patients who are pharmaceutically treated for depression.Abstract

  OBJECTIVE: To examine the associations between pharmaceutically treated anxiety and depression and incident cardiovascular disease (CVD) among 1-year prostate cancer survivors. PATIENTS AND METHODS: A registry-based cohort study design was used toescribe the risk of incident CVD in adult 1-year prostate cancer survivors without a history of CVD

  Wollersheim BM, Boekhout AH, van der Poel HG, van dePoll-Franse LV, Schoormans D. BJU Int. 2019 Nov 26;

• Differential effects on out-of-hospital cardiac arrest of dihydropyridines: real-world data from population-based cohorts across two European countries.Abstract

  AIMS: Various drugs increase the risk of out-of-hospital cardiac arrest (OHCA) in the general population by impacting cardiac ion channels, thereby causing ventricular tachycardia/fibrillation (VT/VF). Dihydropyridines block L-type calcium channelsbut their association with OHCA risk is unknown. We aimed to study whether nifedipine and/or amlodipine, often-used dihydropyridines, are associated with increased OHCA risk, and how these drugs impact on cardiac electrophysiology

  Eroglu TE, Mohr GH, Blom MT, Verkerk AO, Souverein PC, Torp-Peder sen C, Folke F, Wissenberg M, van den Brink L, Davis RP, deBoer A, Gislason GH, Tan HL. Eur Heart J Cardiovasc Pharmacother. 2019 Sep 11;

• Amiodarone use and the risk of acute pancreatitis: Influence of different exposure definitions.Abstract

  PURPOSE: The antiarrhythmic drug amiodarone has a long half-life of 60 days, which is often ignored in observational studies. This study aimed to investigate the impact of different exposure definitions on the association between amiodarone use andthe risk of acute pancreatitis. METHOD: Using data from the Dutch PHARMO Database Network, incident amiodarone users were compared to incident users of a different type of antiarrhythmic drug

  Hempenius M, Groenwold RHH, de Boer A, Klungel OH, Gardarsdottir H. Pharmacoepidemiol Drug Saf. 2019 Aug 2; 28 1563-1571.

• Risk of myocardial infarction associated with non-steroidal anti-inflammatory drugs: Impact of additional confounding control for variables collected from self-reported data.Abstract

  WHAT IS KNOWN AND OBJECTIVE: Important risk factors and over-the-counter (OTC) dispensing of non-steroidal anti-inflammatory drugs (NSAIDs) are often not routinely recorded in electronic health records. This study aimed to assess the impact of patint’s reports on these factors on the risk of acute myocardial infarction (AMI) for NSAID use

  Bakhriansyah M, Souverein PC, de Boer A, Klungel OH. J Clin Pharm Ther. 2019 Apr 7; 44 623-631.

• Effects of European Society of Cardiology guidelines on medication profiles after hospitalization for heart failure in 22,476 Dutch patients: from 2001 until 2015.Abstract

  Prescriber adherence to guideline-recommended medication in patients with heart failure (HF) in clinical practice is suboptimal. We analyzed how evolving guideline recommendations influenced medication profiles after a first HF hospitalization. Wextracted medication profiles from the Dutch PHARMO Database Network for 22,476 patients with a diagnosis of HF at hospital discharge between 2001 and 2015

  Kruik-Kolloffel WJ, Linssen GCM, Kruik HJ, Movig KLL, Heintjes EM, van der Palen J. Heart Fail Rev. 2019 Mar 8; 24 499-510.

• Real-world insights into risk of developing cardiovascular disease following GnRH agonists versus antagonists for prostate cancer: a methodological protocol to a study using five European databases.Abstract

  One of the more recently investigated adverse long-term side effects of gonadotropin-releasing hormone (GnRH) agonists for prostate cancer (PCa) is cardiovascular disease (CVD). Studies suggest lower risk of CVD following GnRH antagonists (degareli) than GnRH agonists. This protocol describes precise codes used to extract variables from five European databases for a study that compares risk of CVD following GnRH agonists and antagonists for PCa

  George G, Scailteux LM, Garmo H, Balusson F, Cardwell C, DeCoster G, DeSchutter H, Kuiper JG, McMenamin U, Verbeeck J, VanHemelrijck M. Fundam Clin Pharmacol. 2019 Feb 18; 33 479-499.

• Nierfunctie en ernstige bloedingen bij patienten behandeld met cumarines.Abstract

  BACKGROUND: Although anticoagulation therapy is closely monitored in the Netherlands, coumarin-induced serious bleeding events are still observed. Current literature suggests that renal impairment may contribute to this. OBJECTIVE: To explore the asociation between renal function and bleeding events during coumarin treatment

  Houben E, Smits E, Overbeek JA, Penning-van Beest FJA, Herings RMC, van Herk-Sukel MPP, Teichert M, de Smet Pagm. Pharmaceutisch Weekblad. 2019 154 19-28.

• No Evidence for an Association Between Renal Function and Serious Bleeding Events in Patients Treated With Coumarins: A Population-Based Study.Abstract

  BACKGROUND: Although anticoagulation therapy is closely monitored in the Netherlands, coumarin-induced serious bleeding events are still observed. Current literature suggests that renal impairment may contribute to this. OBJECTIVE: To explore the asociation between renal function and bleeding events during coumarin treatment

  Houben E, Smits E, Overbeek JA, Penning-van Beest FJA, Herings RMC, van Herk-Sukel MPP, Teichert M, de Smet Pagm. Ann Pharmacother. 2018 Oct 01; 52 221 - 234.

• Relation Between Different Measures of Glycemic Exposure and Microvascular and Macrovascular Complications in Patients with Type 2 Diabetes Mellitus: An Observational Cohort Study.Abstract

  INTRODUCTION: This retrospective cohort study investigated the relation between different measures of glycemic exposure and micro- and macrovascular complications among patients with type 2 diabetes. METHODS: The analysis included patients receivinoral antihyperglycemic agents between 1 January 2006 and 31 December 2014 from the General Practitioner Database from the PHARMO Database Network

  van Wijngaarden RPT, Overbeek JA, Heintjes EM, Schubert A, Diels J, Straatman H, Steyerberg EW, Herings RMC. Diabetes Ther. 2017 Sep 18; 1097-1109.

• Use of antihistamines and risk of ventricular tachyarrhythmia: a nested case-control study in five European countries from the ARITMO project.Abstract

  PURPOSE: After regulatory restrictions for terfenadine and astemizole in ’90s, only scarce evidence on proarrhythmic potential of antihistamines has been published. We evaluate the risk of ventricular tachyarrhythmia (VA) related to the use of indiidual antihistamines. METHODS: A matched case-control study nested in a cohort of new users of antihistamines was conducted within the EU-funded ARITMO project

  Poluzzi E, Diemberger I, DeRidder M, Koci A, Clo M, Oteri A, Pecchioli S, Bezemer I, Schink T, PilgaardUlrichsen S, Boriani G, Sturkenboom MCJ, DePonti F, Trifiro G. Eur J Clin Pharmacol. 2017 Aug 22; 1499 - 151.